Dicerna to Present at 2014 Leerink Global Healthcare Conference on February 13th

Leerink Global Healthcare Conference 2014

WATERTOWN, Mass.--()--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company’s President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:00 PM ET in New York, NY.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Contacts

Investors:
Dicerna Pharmaceuticals, Inc.
James E. Dentzer, 617-612-6204
Chief Financial Officer
or
Media:
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
Senior Vice President
chris@macbiocom.com

Sharing

Contacts

Investors:
Dicerna Pharmaceuticals, Inc.
James E. Dentzer, 617-612-6204
Chief Financial Officer
or
Media:
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
Senior Vice President
chris@macbiocom.com